Webinar

CRISPACT (L. crispatus M247): an effective tool to counteract vaginal dysbiosis

Format: External webinar | Document type: Webinar

CRISPACT (L. crispatus M247): an effective tool to counteract vaginal dysbiosis

Related categories: Probiotics and prebiotics

The different CSTs (Community State Type) are the cause of vaginal health or dysbiosis. CST I, characterised by L. crispatus dominance, is the one that best stabilises and protects the vaginal environment. CRISPACT( L. crispatus M247) is the only marketed product based on such lactobacillus with several clinical evidences on PubMed about vaginal efficacy and colonisation. Its unique characteristics makes CRISPACT an important tool in the prevention and treatment of women with vaginosis and vaginitis, clinically proven.The product is also useful in women with HPV, both in the preventive and therapeutic fields. Its non-transferable resistance to metronidazole also makes it a unique tool of its kind, in this case making it possible to co-administer the probiotic with the antibiotic drug in question. 

Watch Now

Speaker

Francesco Francesco Di Pierro Scientific and Research Director
Velleja Research and MyMicrobiota